Literature DB >> 15280405

Proliferative activity in postmenopausal endometrium: the lurking potential for giving rise to an endometrial adenocarcinoma.

E Sivridis1, A Giatromanolaki.   

Abstract

AIMS: To investigate proliferation in disease free postmenopausal endometrium and that harbouring endometrial adenocarcinoma-is there a dynamic, yet lurking, potential for atrophic endometrium to give rise to endometrial adenocarcinoma? MATERIAL/
METHODS: The study comprised 84 disease free endometria from asymptomatic postmenopausal women who had undergone hysterectomy for prolapse, and 50 endometrioid cell type endometrial adenocarcinomas with adjacent uninvolved postmenopausal endometrium. The non-neoplastic tissues were separated histologically into active, inactive, and mixed forms, although only the first two categories were studied immunohistochemically for oestrogen and progesterone receptors (ERs, PRs), epidermal growth factor receptor (EGFR), Ki-67, and angiogenic activity.
RESULTS: All postmenopausal endometria were atrophic, but only 42 were inactive; of the remaining samples, 22 were weakly proliferative and 20 were mixed active and inactive. In contrast, the non-neoplastic component of 43 of the 50 endometrial adenocarcinomas examined was of the active form; four specimens were of the pure and 39 of the mixed form. Interestingly, high ER and PR expression was seen in active and inactive endometria, but only the former were EGFR positive and had high proliferative (Ki-67) and angiogenic activity. A similar trend was also shown by the non-neoplastic atrophic endometrium adjacent to endometrial adenocarcinoma.
CONCLUSIONS: At least half of the disease free postmenopausal atrophic endometria show a weak proliferative pattern, either diffuse or focal, probably as a response to continuous low level oestrogenic stimulation. These tissues have a latent, although very small, carcinogenic potential, as demonstrated by the immunohistochemical profile and their frequent association with adjacent endometrial adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15280405      PMCID: PMC1770392          DOI: 10.1136/jcp.2003.014399

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  36 in total

1.  Pre-menopausal cystic hyperplasia and endometrial carcinoma.

Authors:  J M McBRIDE
Journal:  J Obstet Gynaecol Br Emp       Date:  1959-04

2.  Predicting response to endocrine therapy in human breast cancer: a hypothesis.

Authors:  K B Horwitz; W L McGuire
Journal:  Science       Date:  1975-08-29       Impact factor: 47.728

3.  Endometrial morphology in asymptomatic postmenopausal women.

Authors:  D F Archer; K McIntyre-Seltman; W W Wilborn; E A Dowling; F Cone; G W Creasy; M E Kafrissen
Journal:  Am J Obstet Gynecol       Date:  1991-08       Impact factor: 8.661

4.  Papillary carcinoma of the endometrium: morphometric predictors of survival.

Authors:  R I Demopoulos; E Genega; E Vamvakas; E Carlson; K Mittal
Journal:  Int J Gynecol Pathol       Date:  1996-04       Impact factor: 2.762

5.  Epidermal-growth-factor receptor correlates negatively with cell density in cervical squamous epithelium and is down-regulated in cancers of the human uterus.

Authors:  D Pfeiffer; R Kimmig; J Herrmann; M Ruge; A Fisseler-Eckhoff; P Scheidel; A Jensen; H Schatz; A Pfeiffer
Journal:  Int J Cancer       Date:  1998-02-20       Impact factor: 7.396

6.  Thymidine phosphorylase expression in normal and hyperplastic endometrium.

Authors:  E Sivridis; A Giatromanolaki; M I Koukourakis; R Bicknell; A L Harris; K C Gatter
Journal:  J Clin Pathol       Date:  2000-09       Impact factor: 3.411

Review 7.  Intratumoral aromatase in human breast, endometrial, and ovarian malignancies.

Authors:  H Sasano; N Harada
Journal:  Endocr Rev       Date:  1998-10       Impact factor: 19.871

8.  Expression of epidermal growth factor receptors in human endometrial carcinoma.

Authors:  H C Nyholm; A L Nielsen; B Ottesen
Journal:  Int J Gynecol Pathol       Date:  1993-07       Impact factor: 2.762

9.  Expression of epidermal growth factor family proteins and epidermal growth factor receptor in human endometrium.

Authors:  H Niikura; H Sasano; K Kaga; S Sato; A Yajima
Journal:  Hum Pathol       Date:  1996-03       Impact factor: 3.466

10.  Effects of aging and obesity on aromatase activity of human adipose cells.

Authors:  W H Cleland; C R Mendelson; E R Simpson
Journal:  J Clin Endocrinol Metab       Date:  1985-01       Impact factor: 5.958

View more
  5 in total

1.  Effect of hormone replacement therapy on postmenopausal endometrial bleeding.

Authors:  Zoltan Magyar; Eniko Berkes; Zsolt Csapo; Zoltan Papp
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

2.  Spontaneous Reproductive Tract Lesions in Aged Captive Chimpanzees.

Authors:  B K Chaffee; A P Beck; M A Owston; S Kumar; W B Baze; E R Magden; E J Dick; M Lammey; C R Abee
Journal:  Vet Pathol       Date:  2016-01-28       Impact factor: 2.221

3.  Proliferation in Postmenopausal Endometrial Polyps-A Potential for Malignant Transformation.

Authors:  Lina Adomaitienė; Rūta Nadišauskienė; Mahshid Nickkho-Amiry; Arvydas Čižauskas; Jolita Palubinskienė; Cathrine Holland; Mourad W Seif
Journal:  Medicina (Kaunas)       Date:  2019-08-28       Impact factor: 2.430

4.  Insulin/IGF and sex hormone axes in human endometrium and associations with endometrial cancer risk factors.

Authors:  Melissa A Merritt; Howard D Strickler; Mark H Einstein; Hannah P Yang; Mark E Sherman; Nicolas Wentzensen; Jurriaan Brouwer-Visser; Maria Jose Cossio; Kathleen D Whitney; Herbert Yu; Marc J Gunter; Gloria S Huang
Journal:  Cancer Causes Control       Date:  2016-04-28       Impact factor: 2.506

5.  Androgen receptors are acquired by healthy postmenopausal endometrial epithelium and their subsequent loss in endometrial cancer is associated with poor survival.

Authors:  A M Kamal; J N Bulmer; S B DeCruze; H F Stringfellow; P Martin-Hirsch; D K Hapangama
Journal:  Br J Cancer       Date:  2016-03-01       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.